Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Just tuned in. I think Pablo has nailed it in his post at 10.05 today. This is a white flag from Blue Star, they have no funds to further invest in Spay, BLU is inviting low ball bids for its large stake. As usual shareholders likely to get shafted, value will be way below what most holders need to break even. It about time Spay started to hit a lot of these missed milestones. If they do then value should quickly rise.
Latest share price ACUT is $0.75. So not too bad.
Saw a news item yesterday (can`t remember what) which made me think if it were a success it would render stemprinter redundant. Market catch up today?
Very heavy on the business outreach angle, very light on the considerable technical developments detail. I am hoping the 9 stages/steps to be completed by the end of 2023 will be grouped such that we may have say three announcements for the completion of all stages of the roadmap.
BLU may not be a direct crypto play but it is in indirect one and the rising values of crypto does look to float all boats. I still stick to my prediction that December 2023 will be a good month for BLU. However I think Q2/Q3 2024 will be our time.
I have said this before, but I believe that Tiziana`s delivery system and Foralumab are 50% of a potential blockbuster drug. TLSA have stated Foralumab is suitable for joint formulation with other drugs. Therefore the Munich conference is exactly the forum to to exchange ideas and pursue partnerships with other drug developers in the CNS field.
So if Stalicla are designing a phase 2 trial, they will not start it until they are granted IND status by the FDA? IND status and the already successful coated tablet trial could bring EVG $5.5m in milestone payments earlier than expected in 2024?
CJ, Thanks for the clarification.
Just reviewed the RNS dated 10/10/2022 announcing the Stalicla collaboration, and the timetable for progression. The SFX enteric coated tablet development was a success RNS 22/3/2023. The human volunteer Phase 1 study using the EC tablet was a success RNS 15/8/2023. Therefore looks to me as if a milestone payment of $0.5m is due from Stalicla? Also $5 million is due as a milestone payment if the FDA grants Investigational New Drug (IND) status to Stalicla. We should expect these payments before the end of 2023?
Thanks for posting Paul. This is great news for Tiziana and the patients.
On the news button above last week.
Trading statement listed for tomorrow, Thursday 12th.
Zero news as to when or even if they still plan to list on NASDAQ. If they got bought out before a float I think getting our money would be a nightmare.
STL, That I think is an accurate enough summary. I am just going to hold on to these shares in the expectation (hope) that Dynasty will continue to make gains in its market share , expand and finally float via an IPO on NASDAQ. SPay is clearly behind its target timeframes. Cracking the decentralised finance nut maybe harder than expected. So there is no guarantee there. It could take another 12 to 18 months to realise value here. Just my view.
There appears to be either a forced seller or a planned sell off by a major shareholder.
Thanks for the link. Positive news. Shares up 1% at $0.77!!!